| INTRODUCTION
Bile acid diarrhoea is a putative pathophysiology of 10%-30% of patients with chronic diarrhoea or diarrhoea-predominant irritable bowel syndrome (IBS-D) and of~1% of the entire population.
1-3 Bile acids are detergent molecules produced by the liver and released into the GI tract in response to a meal to assist with fat emulsification and absorption. Approximately 95% of bile acids are reabsorbed in the terminal ileum. 3 When excess bile acids reach the colon and the associated bacteria, they interact with the G-protein coupled bile acid receptor 1 (GPBAR1 or TGR5), resulting in increased colonic motility, transit, visceral sensation, fluid secretion and mucosal permeability. 4 Studies have demonstrated that there is a limited role of increased bile acid synthesis from the liver in the aetiology of bile acid diarrhoea. 3 Bile acid diarrhoea is characterised into three major categories, based on underlying pathophysiology: type 1-ileal disease, indicating poor bile acid reabsorption in the ileum; type 2-idiopathic, seen in IBS-D; or type 3-secondary causes of bile acid diarrhoea, such as small intestinal bacterial overgrowth, cholecystectomy and chronic pancreatitis. 5 Treatment with bile acid sequestrants (such as colesevelam, cholestyramine and colestipol) has demonstrated an 80%-96% response in patients with moderate to severe bile acid diarrhoea (selenium-75-labelled homocholic acid conjugated taurine [ 75 SeHCAT] retention <10%). 2, 6 Although the main effect of bile acid sequestrants is to bind bile acids, these medications are nonspecific in their binding properties and they can potentially affect other mechanisms associated with diarrhoea. For example, bile acid sequestrants bind Clostridium difficile toxin 7, 8 and decrease C. difficile spore colony formation in mice, 9 change virulence of vibrio, 10 promote eubiosis, 11 and treat bacterial infection in mammals. 12 Therefore, although bile acid binders are utilised in clinical practice when bile acid diarrhoea is suspected and there are no easily available diagnostic tests, a positive response does not necessarily confirm the diagnosis.
The gold standard test used to diagnose bile acid diarrhoea is the 75 SeHCAT retention test. However, this test requires ingestion of a radio-labelled bile acid derivative; whole-body gamma camera scans at baseline and after 7 days, and is unavailable in the United Participants provided a fasting blood sample before 9.00 AM (66%) or 10.00 AM (90%) for the measurements of C4 and FGF19.
We had prior measurements of C4 and FGF19 in 37 of the same participants performed at least 5 years previously, and the recorded values were used for analysis of replicate samples from the same patients ( Figure 1 ).
| Serum 7a-hydroxy-4-cholesten-3-one (C4)
The C4 assay performed in our center (adapted from Galman et al. 21 )
is based on high performance liquid chromatography/tandem mass spectrometry. 22 We utilised C4 ≥52. were recorded data on 48hour faecal bile acid excretion from 30 participants ( Figure 1 ). The faecal bile acid assay and method of measurement were described in previous studies. 25 Patients were defined as having bile acid diarrhoea, based on a faecal bile acid cut off ≥2619 lmol/48 hours. We compared bile acid diarrhoea diagnosis with the individual serum biomarkers. 14 
| Statistical analysis
We used Spearman correlation between the prospectively collected C4 and FGF19 data and the replicate data. Pattni et al. utilised an index equation to adjust for body mass index (BMI) and age for serum FGF19 values. 11 Therefore, we analysed BMI and age as covariates for the fasting serum biomarkers with a linear model using SAS/STAT software (version 9.4, SAS Institute Inc., Cary, NC). BlandAltman plots were used to assess the variability among the replicate samples to appraise the performance characteristics of the tests. To help understand any changes in bowel function in the patients with replicate serum biomarkers, we performed analysis using two-tailed, paired t-test to compare bowel movements and stool consistency in those patients appraised at least 5 years apart. By comparison to the 48-hour faecal bile acid excretion, we calculated specificity, sensitivity, negative predictive value (NPV), and positive predictive value (PPV) for both serum biomarkers. In addition, we determined the sensitivities and specificities of C4 and FGF19 in combination, assuming both serum tests would be performed together rather than sequentially.
3 | RESULTS To compare (see below) the serum biomarkers with the current gold standard in the USA, which is total faecal bile acid excretion, we included data from another 39 patients who had serum C4 and FGF19, as well as total 48-hour faecal bile acid excretion. demonstrated high NPV and specificity for both markers 79%/83% and 78%/78% respectively. When combining C4 and FGF19 together, the sensitivity increased to 50% and the specificity was 65%. When we excluded patients with cholecystectomy, serum C4
| Demographics

| Comparison of serum biomarkers and faecal bile acid excretion
showed 40% sensitivity, 85% specificity, 40% PPV and 85% NPV to diagnose bile acid diarrhoea. For FGF19, exclusion of patients with prior cholecystectomy resulted in 20% sensitivity, 75% specificity, 17% PPV and 79% NPV to diagnose bile acid diarrhoea.
| Replication cohort
From our prior cohort, there were an additional 39 patients diagnosed with IBS-D with C4 and 38 patients with FGF19. Utilising the new fasting serum biomarker cut-offs, the prevalence of bile acid diarrhoea was 23% based on C4 and 34% based on FGF19.
In the entire patient database of 140 patients, including patient 
| DISCUSSION
In this study, we have analysed replicate fasting serum FGF19 and C4 values in patients with FD and IBS-D. The participant demographics were similar (including psychosomatic scores) to those participating in previous studies with IBS-D and chronic diarrhoea at our center. 26 We have observed significant correlations in replicate serum C4 measurements, as well as high levels of specificity and NPVs relative to faecal bile acid measurements. Thus, our findings suggest that serum C4 and FGF19 are biomarkers that can be used as screening methods for bile acid diarrhoea, using the cut-offs ≥52.1 ng/mL and ≤61.7 pg/mL respectively. The serum biomarkers | 585
by Bajor et al. 27 Participants with 75 SeHCAT retention ≤20% were treated on colestipol. Responders were defined by a decrease in symptoms and number of bowel movements by 50%. The responders were noted to have an average C4 value of 55 ng/mL. 27 Although the number of participants in our study was relatively small for the comparison to the gold standard of total faecal bile acid excretion over 48 hours, it demonstrated a high specificity and NPV of fasting serum C4 and FGF19.
Our observations confirm those reported in the literature for studies of the individual biomarkers, serum C4 and FGF19. Sauter et al.
demonstrated C4 sensitivity, specificity, PPV, and NPV of 90%, 79%, 73% and 92%, respectively, for C4 ≥48 ng/mL and
75
SeHCAT <10%.
Our data demonstrated a higher specificity (83%) with a higher cut-off of 52.5 ng/mL. The higher PPV observed by Sauter et al. is based on the increased prevalence of bile acid diarrhoea in that cohort of 17/24
(71%) patients with type 1 and type 3 bile acid diarrhoea. 28 Pattni et al.
described sensitivity and specificity of 58% and 84%, respectively, for FGF19 ≤145 pg/mL as compared to 75 SeHCAT retention values of <10%. Sensitivity increased to 68% when FGF19 values were combined with serum C4, BMI and patient age. 17 These differences in the observed sensitivity and specificity may be related to the differences in the diagnostic yield of 75 SeHCAT compared to faecal bile acid measurements and different cut-off points used in different studies.
Our study also evaluated the concordance of these biomarkers on A concern in our study is the interpretation from the observation of discordant serum biomarkers. Five patients had similar interpretation of the C4 and FGF19 values on repeat testing, but the results were not consistent with the faecal bile acid data. Pattni et al. 17 suggested that combining the two serum biomarkers increased the yield for bile acid diarrhoea diagnosis. Our data combining C4 and FGF19
confirmed that recommendation, since there was improved sensitivity (50%) when considering C4 and FGF19 together (in parallel analysis). However, the specificity for diagnosis of bile acid diarrhoea was lower with the combination of C4 and FGF19, and this is demonstrated by the observation that five patients with positive combined serum C4 and FGF19 had negative faecal bile acid excretion results.
Currently, we are unable to recommend just one blood test for bile acid diarrhoea diagnosis, but the serum C4 test appears to be most reliable as a screening test to exclude bile acid diarrhoea in view of the higher NPV and specificity, and the more consistent values of normal C4 levels on replicate testing, as shown in the Bland-Altman plot.
Based on previous reports and our data, C4 has high specificity and reproducibility, particularly in patients with no evidence of bile acid diarrhoea. Combining both C4 and FGF19 can help increase the diagnostic yield for bile acid diarrhoea. We believe that these serum biomarkers are a good screening method for bile acid diarrhoea.
Without such a simple screening method, patients may choose to forgo the arduous 48-hour faecal bile acid test and proceed with a therapeutic trial of bile acid sequestrants. However, these agents are nonspecific in their binding properties and are not a reliable test to diagnose bile acid diarrhoea. [7] [8] [9] [10] In addition, the cost of full dose colesevelam (1.875 g, b.i.d.) in USA for 4 weeks is about fivefold higher than the cost of measurements of serum C4 and FGF19.
Since the serum biomarkers predict the response to bile acid sequestrants 30 and are cost-efficient compared to a 4-week therapeutic trial, we believe they have a place as first-line tests and, if necessary, can be followed by confirmatory diagnostic tests such as total faecal bile acid excretion or, where available, 75 SeHCAT retention test.
Such a diagnostic approach would also decrease the risk of adverse effects from unnecessary treatment.
Future directions for this research include additional confirmatory testing of the diagnostic performance of fasting serum C4 and FGF19
with tests such as 75 SeHCAT or 48-hour faecal bile acid, based on availability, as well as conducting studies to understand why replicate C4
and FGF19 values change over time and if symptoms and severity change in accordance with the observed variation in the biomarker.
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